Group items tagged

European Nutrition and Health Report 2004 - Directory of several studies

European nutrition and health report 2004

Leaflet of the European Nutrition and Health Report 2009 Executive summary of the European Nutrition and Health Report 2004

Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Zhou W, Suk R, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Giovannucci E, Christiani DC. Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2303-9. PMID: 16214909 In conclusion, the joint effects of surgery season and recent vitamin D intake seem to be associated with the survival of early-stage non-small cell lung cancer patients. In summary, for early-stage NSCLC patients, patients who had surgery in summer with "high" recent vitamin D intake have a statistically significantly improved RFS and OS than patients who had surgery in winter with "low" vitamin D intake. These results should be confirmed in a prospective study to assess the serum vitamin D levels at time of surgery. If the results are confirmed, our results, combined with findings in other studies, suggest that dietary vitamin D supplementation may be advisable for early stages of lung cancer patients, particularly during the winter season and in groups that tend to be deficient in vitamin D.

Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Pérez-Castrillón JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G, Dueñas A. Am J Cardiol. 2007 Apr 1;99(7):903-5. Epub 2007 Feb 8. PMID: 17398180 In conclusion, atorvastatin increases vitamin D levels. This increase could explain some of the beneficial effects of atorvastatin at the cardiovascular level that are unrelated to cholesterol levels. The mechanism by which atorvastatin increases vitamin D levels is related to inhibition of 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase. Cholesterol is synthesized from 7-dehydrocholesterol, which is also a precursor of vitamin D3. For this reason, we initially observed a statistically significant relation between total cholesterol and vitamin D. HMG-CoA enzyme reductase is key to the synthesis of cholesterol, whereas ultraviolet radiation causes the formation of 25-hydroxyvitamin D. Inhibition of the enzyme may increase levels of 7-dehydrocholesterol and increase the synthesis of 25-hydroxycholecalciferol, thereby increasing vitamin D levels,10 although we observed no relation between lower cholesterol and increased vitamin D. In addition, 25-hydroxyvitamin D has been shown to inhibit HMG-CoA enzyme reductase activity in in vitro studies.11 A greater concentration of vitamin D could increase enzymatic inhibition, acting in synergy with the statin in decreasing total cholesterol.

Statins and vitamin D. Aloia JF, Li-Ng M, Pollack S. Am J Cardiol. 2007 Oct 15;100(8):1329. Epub 2007 Jul 5. No abstract available. PMID: 17920383 A total of 208 women were randomized to receive vitamin D3 (n=104) or placebo (n=104). 51 women were on statins. At baseline, the subjects on statins had a significantly higher 25-OHD level than the subjects who were not on statins (51.2 ± 20.1 nmol/L versus 43.2 ± 18.0 nmol/L respectively, p=0.008). This was also true when averaging 25-OHD levels across the 3-year study period and looking at active and placebo patients separately. 185 subjects had follow-up 25-OHD levels drawn every 6 months during the study. Higher levels were seen in the statin use subgroup whether they were on placebo or active vitamin D (Figure 1Figure 1). There was no interaction seen between vitamin D use and statin use, i.e. the impacts are additive (p=0.5502). This significant difference is comparable to the increase in 25-OHD levels seen in Pérez-Castrillón's study (41 ± 19 versus 47 ± 19 nmol/L, p=0.003) [1]. Although Pérez-Castrillón et al found a statistically significant relation between total cholesterol and 25-OHD (r=0.277, p=0.002), we did not find a significant relation between total cholesterol and 25-OHD in our study population.

"Largest-ever meta-analysis finds CRP is unlikely to be causal for CVD December 21, 2009 | Lisa Nainggolan Cambridge, UK - In the largest and most comprehensive meta-analysis to date looking at C-reactive-protein (CRP) levels and risk of coronary heart disease (CHD) and stroke, British researchers conclude that CRP is unlikely to be a causal factor for cardiovascular disease [1]. Although CRP concentration was linearly associated with CHD, stroke, and vascular mortality, as well as nonvascular mortality, statistical adjustment for conventional cardiovascular risk factors "resulted in considerable weakening of associations," note the scientists of the Cambridge-based Emerging Risk Factors Collaboration (ERFC), who report their findings online December 21, 2009 in the Lancet. In an editorial accompanying the paper [2], Drs S Matthijs Boekholdt and John JP Kastelein (Academic Medical Center, Amsterdam, the Netherlands) say the UK authors "are to be commended for this impressive data set." Although the findings "add weight to the evidence of noncausality" for a role of CRP in the development of cardiovascular disease, "the debate can be resolved only by randomized trials with agents that specifically target CRP, and such compounds are currently under development," say the Dutch doctors. Commenting on the new meta-analysis for heartwire, Dr Paul Ridker (Brigham and Women's Hospital, Boston, MA), a long-time advocate of CRP and the lead investigator of the JUPITER trial, said: "Whether or not CRP is 'causal' for heart disease is neither the crucial issue at hand nor relevant for public health. What is crucial is getting international agreement that CRP identifies higher-risk individuals who would not otherwise qualify for a life-saving therapy, and then showing that such individuals clearly benefit from treatment. The new meta-analysis demonstrates the former, and JUPITER demonstrates the latter." "

"Study highlights: * Ginkgo biloba doesn't prevent cardiovascular death, heart attacks or strokes, and should not be recommended as a way to prevent them. * Further research should explore its potential benefit to people with peripheral vascular disease. DALLAS, Nov. 24, 2009 - Ginkgo biloba didn't prevent cardiovascular death or major events such as heart attack and stroke in people age 75 and older, but the herb may affect peripheral vascular disease, according to research reported in Circulation: Cardiovascular Quality and Outcomes, a journal of the American Heart Association. "Surprisingly, Ginkgo was associated with a reduction in peripheral artery disease, but the number of patients was small. The difference was statistically significant," said Lewis H. Kuller, M.D., Dr.P.H., first author of the study and distinguished university professor of public health and professor of epidemiology at the University of Pittsburgh. Gingko biloba contains a class of nutrients - flavonoids - found in fruits, vegetables, dark chocolate and red wine, which are believed to offer some protection against cardiovascular events. "

"(NaturalNews) The emu, a native of Australia, is a large, ostrich looking bird that doesn't fly. The Australian Aborigines first discovered the benefits of emu oil and have been using it for thousands of years for bone, muscle and joint pain, as an anti-inflammatory and for many skin conditions. The west is finally taking notice of this remarkable oil. Red Meat with No Worries Although a bird, the emu meat is red and a healthy alternative to traditional red meat. It's naturally 97% fat free, high in iron and vitamin B12 and low in calories and cholesterol. As the meat is packaged and sold, the oil is purified and sold separately. Benefits of Emu Oil Emu oil consists of oleic acid (a mono-unsaturated omega-9 fatty acid), linoleic acid (omega-6 fatty acid) and linolenic acid (an omega-3 fatty acid). The benefits are thought to be due to the ability of the oil to deeply penetrate the skin layers. Linoleic acid (omega-6 fatty acid) is believed to ease muscle aches and joint pain. Oleic acid (omega-9 fatty acid) is considered to have local anti-inflammatory effect (similar to ibuprofen). Studies suggest emu oil is bacteriostatic (does not promote growth of bacteria) and hypoallergenic (won`t cause irritation); it does not leave a greasy feel, and it is non-comedogenic, which means it won`t clog pores. Side effects are virtually unknown with emu oil. Several small clinical studies reported successful results for temporary relief of muscle and joint pain, specially related to arthritis. Emu Oil and Burn Wounds A long-term study by Dr. John Griswold, Director of the Timothy J. Harner Burn Center (affiliated with Texas Tech University Medical Center, Lubbock, Texas) in 1995 found that there was statistically significant difference in scar reduction and inflammation of the emu oil treated wounds. Other benefits found from studies from Department of Dermatology, at Texas Medical School in Houston, proved emu oil does not clog skin pores and has anti-aging properties."

At any given time 15 to 35% of people are trying to loose weight and the statistics are not in their favor. The fact is that 90 to 95 % of those people will fail to loose weight and successfully keep it off.

Calcium:magnesium ratio in local groundwater and incidence of acute myocardial infarction among males in rural Finland. Kousa A, Havulinna AS, Moltchanova E, Taskinen O, Nikkarinen M, Eriksson J, Karvonen M. Environ Health Perspect. 2006 May;114(5):730-4. doi:10.1289/ehp.8438 PMID: 16675428 Results of this study with specific Bayesian statistical analysis support earlier findings of a protective role of Mg and low Ca:Mg ratio against coronary heart disease but do not support the earlier hypothesis of a protective role of Ca

Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M, Keck PE Jr, Marangell LB, Richardson AJ, Lake J, Stoll AL. J Clin Psychiatry. 2006 Dec;67(12):1954-67. Review. Erratum in: J Clin Psychiatry. 2007 Feb;68(2):338. PMID: 17194275 Conclusions: The preponderance of epidemiologic and tissue compositional studies supports a protective effect of omega-3 EFA intake, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in mood disorders. Meta-analyses of randomized controlled trials demonstrate a statistically significant benefit in unipolar and bipolar depression (p=.02). The results were highly heterogeneous, indicating that it is important to examine the characteristics of each individual study to note the differences in design and execution. There is less evidence of benefit in schizophrenia. EPA and DHA appear to have negligible risks and some potential benefit in major depressive disorder and bipolar disorder, but results remain inconclusive in most areas of interest in psychiatry. Treatment recommendations and directions for future research are described. Health benefits of omega-3 EFA may be especially important in patients with psychiatric disorders, due to high prevalence rates of smoking and obesity and the metabolic side effects of some psychotropic medications.

"The gluten/schizophrenia connection has been tossed around since the 1970's. It is still controversial. Yet, some with schizophrenia (statistics say around 10-20%) may be miraculously helped by a simple dietary change. It is important to realize that many people have problems with gluten who do not test positive for Celiac Disease. Gluten can cause different types of problems. Casein sensitivity may be involved as well, for some."

A cancer registry is the cancer cases which are registered in a population or specific country. In whole world mortality rate due to cancer is 20%. In USA cancer is the second largest disease of causing death after heart disease. Recently in 2016 estimated that 595,690 people die from this disease according to cancer statistics of National Cancer Institute USA.

This database provides both national and sub-national adult underweight, overweight and obesity prevalence rates by country, year of survey and gender. The information is presented interactively as maps, tables, graphs and downloadable documents. These ca

Nutritional Situation of the Elderly in the European Union: Data of the European Nutrition and Health Report (2004) Elisabeth Fabian, Ibrahim Elmadfa Ann Nutr Metab 2008;52 (Suppl. 1):57-61 (DOI: 10.1159/000115352)

The Maltese and the Greeks are the heavyweights of Europe, figures from the European Commission reveal. The Italians and French the most trim, while the average Briton - like the average European - is slightly over the ideal weight. Obesity, which is linked to a range of health problems, including heart disease, is a growing problem across much of the developed world.